J. Safra Sarasin Holding’s Denali Therapeutics DNLI Stock Holding History

J. Safra Sarasin Holding’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$804K	Buy	+31,250	New	+$642K	0.01%	440

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

J. Safra Sarasin Holding's DNLI Position: Q2 2026 in Review

J. Safra Sarasin Holding opened a new position in Denali Therapeutics (DNLI) in Q2 2026: 31,250 shares worth $804K. The stake represents 0.01% of the portfolio and ranks #440 among its holdings.

292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

J. Safra Sarasin Holding held 31,250 shares of Denali Therapeutics worth $804K as of Q2 2026.
Denali Therapeutics was a new J. Safra Sarasin Holding position in Q2 2026.
Denali Therapeutics made up 0.01% of J. Safra Sarasin Holding's portfolio in Q2 2026, its #440 holding.
292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on J. Safra Sarasin Holding's 13F filing for Q2 2026, filed 31 Jul 2026.